Cargando…

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer

Detalles Bibliográficos
Autores principales:	Cervantes, A., Prager, G.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Pro and Con Discussions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976207/ https://www.ncbi.nlm.nih.gov/pubmed/36812740 http://dx.doi.org/10.1016/j.esmoop.2023.100883

Ejemplares similares

Anthracyclines in the treatment of patients with early breast cancer
por: Guarneri, V., et al.
Publicado: (2022)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
por: Zand, Ladan, et al.
Publicado: (2023)

Interacting with the Pharmaceutical Industry
por: Hayden, Stephen R.
Publicado: (2003)

Should Academic Emergency Departments Collaborate in Pharmaceutical Industry-Sponsored Research?: The Dangers of Industry-Funded Research in Emergency Medicine
por: Stone, Susan, et al.
Publicado: (2003)

Advantages of a Three-year Residency
por: Langdorf, Mark, et al.
Publicado: (2004)

Why the US Government Should Not Adopt a Universal Health Coverage Program
por: Montauk, Lance
Publicado: (2004)

Con: Should Evidence-Based Medicine Be Used More in Clinical Practice?
por: Maxim, Preston
Publicado: (2006)

Rebuttal of Con
por: Fee, Chris
Publicado: (2006)

Rebuttal of Pro
por: Maxim, Preston
Publicado: (2006)

Pro: Should Evidence-Based Medicine Be Used More in Clinical Practice?
por: Fee, Chris
Publicado: (2006)

Pro: Venoarterial ECMO Should Be Considered in Patients With COVID-19
por: Bhatia, Meena, et al.
Publicado: (2021)

Con: Venoarterial ECMO Should Not Be Considered in Patients With COVID-19
por: McLean, Duncan J., et al.
Publicado: (2021)

Con: Integrated 5-Year Anesthesiology Residency Should Be Implemented Widely
por: Phillips, Thomas
Publicado: (2023)

Pro: Integrated Five-Year Anesthesiology Residency Should Be Implemented Widely
por: Kovar, Alan J., et al.
Publicado: (2023)

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant?: Pro: Provide pre-emptive treatment to asymptomatic carriers
por: de Boer, Rudolf A.
Publicado: (2023)

Congenital nephrotic syndrome: is early aggressive treatment needed? Yes
por: Hölttä, Tuula, et al.
Publicado: (2020)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!
por: Rossignol, Patrick, et al.
Publicado: (2023)

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant?: Con: Do no harm to asymptomatic carriers
por: Doevendans, Pieter A.
Publicado: (2023)

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2011)

Dietary sodium and cardiovascular and renal disease risk factors: dark horse or phantom entry?
por: McCarron, David A.
Publicado: (2008)

Is too much salt harmful? Yes
por: Agócs, Róbert, et al.
Publicado: (2019)

Pro con debates in clinical medicine infection prevention and control in cystic fibrosis: One size fits all? The argument in favour
por: Haggie, S., et al.
Publicado: (2020)

The term CAKUT has outlived its usefulness: the case for the prosecution
por: Woolf, Adrian S.
Publicado: (2022)

The term CAKUT has outlived its usefulness: the case for the defense
por: Knoers, Nine V. A. M.
Publicado: (2022)

Therapy of membranous nephropathy: quo vadis?
por: Glassock, Richard J
Publicado: (2023)

When comparing the safety of drugs, don't forget the exposure dimension
por: Zoccali, Carmine
Publicado: (2023)

Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…
por: Carrero, Juan Jesus, et al.
Publicado: (2023)

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review
por: Walter, H, et al.
Publicado: (2013)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Why the US Should Adopt a Universal Health Care Coverage Program
por: Brown, Lance
Publicado: (2004)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
por: Miyo, Masaaki, et al.
Publicado: (2020)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
por: Loupakis, F, et al.
Publicado: (2013)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

Saying No to Cameras in the Emergency Department
por: Geiderman, Joel
Publicado: (2003)

Pro Position for Filming in The ED
por: Clements, R. Carter
Publicado: (2003)

Rebuttal to “Pro Filming in the ED”
por: Geidesman, Joel
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_416i7gmp4d4g137pegn9o40iu2